Modern and conventional prognostic markers of chronic lymphocytic leukemia in the everyday haematological practice
| Authors | |
|---|---|
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | European Journal of Haematology |
| MU Faculty or unit | |
| Citation | |
| Web | http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2011.01639.x/pdf |
| Doi | http://dx.doi.org/10.1111/j.1600-0609.2011.01639.x |
| Field | Oncology and hematology |
| Keywords | chronic lymphocytic leukemia;cytogenetics;IgVH mutation status;overall survival;prognostic markers |
| Description | Objectives: The impact of modern prognostic markers on clinical course of chronic lymphocytic leukemia (CLL) in everyday practice has been not yet well-defined, especially in large series of patients. Therefore, the goal of the present study was to assess the influence of conventional as well as modern prognostic factors on overall survival (OS) and time to therapy (TTT) of CLL patients. Methods: We retrospectively analyzed data of all patients consecutively entered into the databases of five large academic centers in the Czech Republic. The total of 1300 patients was included in the analysis. Results and conclusion: Through the use of uniparametric analysis, it was determined that gender, clinical stage Rai II-IV, unmutated IgVH status, 17p deletion (for both 5% and 20% cut-off), 11q deletion, ZAP-70 positivity and high expression of CD38 had significant negative influence on OS. TTT was significantly influenced by gender, Rai stage, IgVH status, 11q deletion, 17p deletion, 13q deletion and by CD38 expression. Multiparametric analysis revealed that OS was significantly influenced by gender, age, IgVH status, and 17p deletion. If only patients who died of CLL were included, gender, age, Rai stage, IgVH status, and deletion 17p had significant influence on OS. Based on our results, the examination of biological prognostic markers can give an insight into the possible disease evolution in daily clinical practice. Biological prognostic markers are however not ready (maybe except deletion 17p in younger patients) to be used for guidance of therapy at least outside of clinical trials. |
| Related projects: |
|